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Uppsala University, Department of Oncology, Radiology and Clinical Immunology, Division of Clinical Immunology, The
Rudbeck Laboratory, Uppsala, Sweden
Abstract
Background. Low engraftment and adverse immune reactions hamper the success rate of clinical islet transplantation. In this
study, we investigated the capacity of human mesenchymal stem cells (MSCs) to adhere to human islets of Langerhans and
their effects in immune modulation and during blood interactions in vitro.
Methods. Composite MSC–islets were formed by suspension co-culture, and the phenotype was evaluated by confocal
microscopy. Islet function was assessed by dynamic insulin release in response to glucose in vitro. Mixed lymphocyte–islet
reactions (MLIR) and the tubing blood loop model were utilized as in vitro tools toanalyse the effect of MSCs on the innate and
adaptive immune reactions triggered by the islets.
Results. MSCs rapidly adhered to islets and spread out tocover the islet surface. Insulin expression and secretion were sustained
with the MSC coating. MSC-coated islets showed unaffected reactions with blood in vitro in comparison to control islets.
Furthermore, MSCs suppressed lymphocyte proliferation induced by islet cells in MLIR.
Conclusion.WeconcludethatitispossibletocreatecompositeMSC–isletstoenabledeliveryoftheMSCsbyutilizingtheadhesive
capacity of the MSCs. This could have beneﬁcial immunosuppressive effects in optimizing pancreatic islet transplantation.
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Introduction
Multipotent mesenchymal stromal/stem cells (MSCs)
are adherent cells that reside in the stroma, where they
produce stromal components (1,2). Through their
multipotency MSCs can differentiate towards fat,
bone, or cartilage upon the correct stimuli (1).
MSCs have been shown to possess an immunosup-
pressive capacity and to protect against activated
immune responses (3–5). MSCs can also suppress
adaptive immune reactions (6–9) and have shown a
dramatic positive effect on severe graft-versus-host
disease in humans (10,11). The beneﬁcial effects of
MSCs make them attractive as tolerance-inducing
cells during cell transplantation (3,12,13). Transplan-
tation of islets containing insulin-producing beta cells
is currently evaluated as a treatment for patients with
life-threatening hypoglycaemic episodes and unsatis-
factory glycaemic control despite careful insulin ther-
apy (14). One key factor for successful islet
transplantation is to use a high number of islets, in
part due to loss of islets in response to adverse
immune reactions (15–17). The immunosuppressive
capacity of MSCs, alongside the ability to improve
regeneration of damaged tissue (18–21) and to pro-
vide a supportive stromal environment, could beneﬁt
islet transplantation. MSCs have been isolated from
pancreatic ductal epithelium and may therefore have a
natural role to protect and compose a suitable envi-
ronment for the endocrine cells in the native pancreas
(22). At the same time, the islets provide a surface for
adherence of MSCs which could improve the survival
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actions between islets and MSCs concerning the
potential of MSCs to attach to the islets, and the
consequences this has on insulin secretion of
the islets, blood contact, and immune modulation
by the MSCs in vitro.
Delivery of islets and MSCs separately during
intraportal transplantation will lead to deposition of
MSCs to other sites than the islets. The possibilities to
bind the MSCs to the surface of the islets will not only
make it possible to target the MSCs to the same site as
the islets in the clinical intraportal transplantation, but
also increase the likelihood of initial contact between
the MSCs and the islets. Here we show that the blood
interactions of the MSC–islets in the tubing blood
loop model have no further negative effect upon the
coagulation or the complement system.
Material and methods
Isolation of human islets of Langerhans
Human islets of Langerhans were isolated by the
isolation laboratory of the Nordic Network in Uppsala,
Sweden, as previously described (23), using a modiﬁed
semi-automated digestion-ﬁltration method (24–26).
Pancreases were obtained from brain-dead donors
after appropriate consent for multi-organ donation.
Islet preparations with a purity ranging from 70% to
80% have been analysed in this study. Purity was
estimated by dithizone staining of endocrine islet tis-
sue. Islets were cultured in islet medium: Connaught
Medical Research Laboratories (CMRL) 1066 culture
medium with 10% human ABO serum, 2.4 mM
L-glutamine, 12 mM Hepes, 12 mM nicotinamide,
6 mM sodium pyruvate, 50 mg/mL gentamycine,
20 mg/mL ciproxine, and 0.25 mg/mL fungizone.
Isolation and expansion of adult human MSCs
The human MSCs used in this study were generously
provided by Professor Katarina Le Blanc, Karolinska
Institutet, Stockholm, Sweden. The MSCs were iso-
lated and expanded from bone marrow (BM) as
previously described (27) following the approval by
the ethics committee at Huddinge University Hospi-
tal. The cells were cultured in MSC medium
consisting of Dulbecco’s modiﬁed Eagle’s medium-
low glucose (DMEM-LG), supplemented with 10%
heat-inactivated foetal bovine serum (FBS) (from
PAA, Pasching, Austria) and 1% antibiotic solution.
The cells were classiﬁed as MSCs based on plastic
adherence, differentiation to bone and fat, and
expression of surface markers (28). MSCs in passages
3–9 from 13 donors were used in this study.
Adherence and spreading of MSCs on human islets
Approximately1,000humanisletsweremixedwith1
10
5,2 . 5 10
5,o r5 10
5 MSCs in 1 mL of islet
culture medium. To evaluate the degree of coating, the
MSCs were stained with CellTracker Green according
to the manufacturer’s instructions (Molecular Probes,
Eugene, OR, USA). The MSCs and islets were incu-
bated at 37C for 3 hours in cell suspension tubes,
mixed gently every 30 minutes, and subsequently cul-
tured in islet medium (n = 13). Evaluation of the
adherence and spreading of the MSCs on the islet
surface was performed by confocal laser scanning
microscopy (Zeiss LSM 510 Meta, Carl Zeiss AG,
Göttingen, Germany). To analyse the distribution of
MSCs, within the islets, islet preparations were ﬁxed
for 1 hour at room temperature (RT) in 4% formal-
dehyde, washed in Phosphate Buffered Saline (PBS)
overnight, incubated in 20% sucrose for 12–24 hours,
before being embedded in Optimal Cutting Temper-
ature (OCT) medium (Tissue Tech, Sakura Finetech-
nical,Tokyo,Japan)andsnap-frozeninliquidnitrogen.
Sections of 10 mm were counterstained with 4¢,6¢-
diamidino-2-phenylindole (DAPI) (10 mg/mL, Fluka,
Sigma-Aldrich, St.Louis, MO, USA).
Measurement of insulin release and insulin DNA
The functionality of the islets coated with MSCs com-
pared with control islets from the same isolation was
testedafter48hours.Twentyhand-pickedMSC-coated
and non-coated control islets were challenged in
a dynamic perifusion system, beginning with a
low-glucose concentration (1.67 mmol/L), followed
by a high-glucose challenge (20 mmol/L) and then
re-exposuretothelow-glucoseconcentration.Fractions
were collected at 6-minute intervals over 126 minutes
and analysed for insulin content using commercial
Enzyme-linked immunosorbent assay (ELISA) kits
(Mercodia, Uppsala, Sweden). Stimulation index was
calculated: (average of high-glucose samples)/(average
of low-glucose samples). For measurements of insulin/
DNA ratio, 20 hand-picked MSC-coated and control
isletswerecollectedandanalyzedforinsulincontentby
ELISA (Mercodia). Quant-iT picogreen dsDNA assay
kit(Invitrogen,Carlsbad,CA,USA)wasusedforDNA
measurements and analysed by a ﬂuoroscan ascent
Fluorometer Luminometer (FL) (Thermo Electron
Corp., Waltham, MA, USA).
Immunohistochemistry
Peripheral blood mononuclear cells (PBMC) were
isolated from healthy human volunteers. The blood
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Ficoll gradient (1.077 g/L; Axis-Shield PoC AS, Oslo,
Norway). After three washes in PBS, the cells were
resuspended in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10%
human pooled AB serum, 2 mM L-glutamine,
100 U/mL penicillin, and 100 mg/mL streptomycin
(complete RPMI medium). To obtain single islet cells
the islets were washed twice in PBS and incubated in
Accutase (Sigma-Aldrich) for 10 minutes at 37C. The
reaction was stopped by addition of an equal volume of
cold FBS, and the cell suspension was carefully vor-
texed to dissociate the islets. Responder PBMC
(100,000) and stimulator pancreatic single cells
(100,000) were mixed in 200 mL of complete RPMI
medium intriplicates, without or with10,000 (10%) or
1,000 (1%) of MSCs. Stimulator cells and MSCs were
irradiated and co-cultured for 5 days. The proliferation
of responder PBMC was measured after another
24 hours of tritium-labelled thymidine incorporation
(1 mCi, Radiochemical Centre, Amersham, UK). The
cells were harvested automatically on glass ﬁbre ﬁlters,
using a Tomtec harvesting machine (Harvester 96,
Tomtec, Orange, CT, USA). Two independent
experiments with two islet preparations and in total
four different MSCs were tested (n = 6).
Transplantation of composite islets
Approximately 200 control human islets or an equal
number of MSC-coated human islets were trans-
planted under the kidney capsule of C57BL/6/sca
nu/nu mice (Scanbur AB, Sollentuna, Sweden). After
2 weeks, the kidneys were removed and stained for
insulin (n = 3).
To perform transplantation of syngeneic composite
grafts, mouse islets were isolated and hand-
picked from C57BL/6/sca (Scanbur, Sweden), and
approximately 200 islets were coated with
125,000 murine MSCs derived from C57BL/6/sca,
a kind gift from Professor Raﬁ Gorodetsky, Sharett
Institute of Oncology, Hadassah-Hebrew University
Medical Center, Jerusalem, Israel (29). The islets and
MSC–islets were transplanted under the kidney cap-
sule, and grafts were retrieved 28 days after trans-
plantation (n = 3). Animal handling was performed
with ethical permission approved by the authorities
and according to the UKCCCR guidelines for the
welfare of animals in experimental neoplasia (30).
One-way mixed lymphocyte–islet reactions (MLIR)
Insulin expression in transplanted human islets
was analysed in parafﬁn-embedded tissue. Kidney
biopsies were ﬁxed in 4% paraformaldehyde for
24 hours and prepared for parafﬁn embedding. Sec-
tions were stained for insulin (guinea-pig anti-insulin,
Dako, Glostrup, Denmark) following a secondary
antibody (goat anti-rabbit Envision, Dako). Finally,
the sections were developed in AEC (3-amino,
9-ethyl-carbazole, Dako) and counterstained with
haematoxylin. Transplanted syngeneic MSC–islets
and control islets were prepared as described
above including a decalciﬁcation step according to
manufacturer’s instructions (Pargeny, Histolab,
Gothenburg, Sweden) of the MSC–islet grafts before
sectioning and thereafter haematoxylin and eosin
staining.
The tubing blood loop model
Untreated control human islets and MSC–islets were
exposed to fresh human ABO-compatible blood using
a loop system consisting of polyvinyl chloride (PVC)
tubings with a heparinized inner surface (31). The
loop system was placed on a rocking apparatus in an
incubator at 37C to simulate a blood-ﬂow inside the
PVC tubing. Loops with 7 mL of human blood were
prepared, and 100 mL of PBS (negative control) or
500–800 coated or uncoated islets in 100 mLo fP B S
were added (n = 5). The loops were then closed with a
polypropylene connector and placed in the 37C
incubator on the rocking apparatus. One mL of blood
was collected at 3 different time points (5, 10 and 30
min) in tubes containing 50 mL 0.2 M NaEDTA, pH
7.4, to determine platelet consumption, and plasma
was prepared from the remaining blood in the sample
for ELISA analysis of C3a and thrombin anti-
thrombin (TAT) (Mercodia, Uppsala, Sweden).
Statistical analysis
Statistics were calculated using the Statistica software
(Statsoft Scandinavia AB, Uppsala Sweden). Results
were compared using the non-parametric Wilcoxon
test, and P values £ 0.05 were considered statistically
signiﬁcant.
Results
Adherence and spreading of MSCs
MSCs showed a dose-dependent coating of the islets.
With addition of 100,000 MSCs to approximately
1,000 islets, only a sporadic binding to the islet
surface was detected. Increased coating was observed
10 I. Rasmusson Duprez et al.when 250,000 and 500,000 MSCs were used
(Figure 1A). A further increase in the number of
MSCs did not result in increased coverage. Rather
there were many single cells in suspension, whereas a
proportion of the islets remained free of coating.
When pancreatic islets and MSCs were incubated
together, the MSCs adhered to the islets within
1 hour (Figure 1B). After 5 hours, the MSCs had
initiated spreading and covered most of the islet
surface. After 24–48 hours, the adherence of the cells
was completed with no apparent improvement of
coating nor loss of MSC attachment for up to
96 hours, which was the selected end-point of the
coating experiments (Figure 1B). In addition to coat-
ing the surface of the islets, MSCs were also found
within the islet core (Figure 1C).
Insulin secretion in composite MSC–islets
Functionality of the islets was investigated by insulin
secretioninadynamicperifusionsystem,wheretheislets
were stimulated with different glucose concentrations.
The shift from low to highglucose solution stimulates a
rapid release of insulin. Onaverage, the coating of islets
with MSCs did not affect the insulin secretion by the
islets (Figure 2A, n = 5). The stimulation index was not
signiﬁcantly different between control islets and com-
positeMSC–islets(11.0±5.2forcontrolisletsand9.5±
3.6forMSC–islets,average±SEM,n=5).Additionally,
insulin/DNA ratio (pmol  L
1  ng
1)s h o w e dn o
difference between control islets and composite MSC–
islets, even though the MSCs contributed with DNA in
the insulin and DNA ratio of MSC–islets (Figure 2B,
n = 3). Human islets or composite MSC–islets were
transplanted under the kidney capsule of nu/nu mice,
and all grafts were positively stained for insulin when
retrieved after 2 weeks (Figure 2C, n = 3).
Syngeneic transplantation of mouse MSC–islets
Transplantation of mouse islets, control islets, or
MSC–islets was performed under the kidney capsule
of mice (n = 3). The grafts were removed 28 days after
transplantation. By then, the MSC–islet grafts were
differentiated into bone, and the graft was enlarged in
comparison to control (Figure 3A, B). The bone
formation was further veriﬁed after sectioning followed
by haematoxylin and eosin staining (Figure 3C).
MSCs and islet cells in mixed lymphocyte–islet reactions
(MLIR)
To analyse the immunological effects of MSCs on
immune reactions induced by islets, we cultured
peripheral blood mononuclear cells (PBMC) with
dissociated allogeneic islet cells with or without
allogeneic MSCs in suspension culture during
6 days and studied lymphocyte proliferation by
incorporation of
3H-thymidine during the last
24 hours. MSCs and stimulator cells were irradiated
not to proliferate, to yield a one-way MLIR. The
addition of 10% or 1% MSCs signiﬁcantly sup-
pressed proliferation (Figure 4). The positive control
in which the effector cells reacted against allogeneic
PBMC induced a proliferation of 42,493 ±
15,317 counts perminute (cpm) andreactionagainst
islet cells 9,721 ± 3,796 cpm. The results were
adjusted to per cent response relative to the respec-
tive control without MSCs to adjust for donor
differences.
MSC–islets in the tubing blood loop model
In vitro studies of islets and MSC–islets interactions
with ABO-compatible blood in tubing loops coated
with heparin were investigated. The results showed a
similar reduction in platelets (Figure 5A) and gran-
ulocytes (Figure 5B) and increase in lymphocytes
(Figure 5C) during 30 minutes of incubation in
both groups due to inﬁltration of cells in blood clots.
A similar activation of coagulation occurred by
control islets and MSC–islets as shown by increa-
sed levels of thrombin anti-thrombin (TAT)
(Figure 5D). This effect was also shown by activation
of the complement by increased levels of C3a
(Figure 5E).
Discussion
We have evaluated the possibility to coat human islets
of Langerhans with human MSCs and investigated
their role in islet function in different in vitro
models symbolizing the scenario of clinical islet
transplantation.
I n t r a v e n o u si n j e c t i o n so fM S C si nr o d e n t ss h o w
deposit of the injected cells in the lungs (32), indi-
cating that intravenous administration of the cells
results in entrapment of the cells. The distribution of
MSCs depends on the site of infusion (33–35),
and injuries can alter the distribution pattern with
an increased cell migration to the site of injury
(35,36). We incubated MSCs with islets and studied
adhesion and spreading to the islets for up to
96 hours. In addition to the good capacity to coat
islets, MSCs were also found within the islet core.
Coating of islets with MSCs did not adversely affect
the islet function as conﬁrmed by measuring the
Composite mesenchymal stem cell islets 11insulin release elicited by MSC–islets after 48 hours
of culture. Our results show that the interactions
betweenislets and MSCs are rapidwitha highdegree
of binding within the ﬁrst 24 hours. This is compared
to coating with aortic endothelial cells (EC) that
required up to 7 days for an optimal coverage of
the islet surface (23). The addition of MSCs to
composite EC–islets has previously shown enhanced
A.
B. C.
Figure 1. Coating of pancreatic islets with MSCs. Human islets were coated with CellTracked MSCs (green). A: Dose-dependent coating of
islets with 100,000, 250,000, or 500,000 MSCs after 48 hours of culture. B: The initial adherence and the following spreading of MSCs after 1,
5, 48, and 96 hours of culture. One representative experiment is shown. C: MSCs within the islet core after 48 hours of co-culture, nuclei in
blue. Scale bars = 100 mm.
12 I. Rasmusson Duprez et al.adhesion of the microvascular EC to the islet surface.
Besides facilitating binding of EC to the islet surface,
MSC-conditioned medium stimulated prolifera-
tion of EC (37). Positive effects of MSCs on
revascularization in pancreatic islets have also been
shown in vivo (38).
MSCs can suppress various immune responses
(reviewed in (39)). In this study, we have analysed
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Figure 2. Insulin secretion and expression in MSC-coated islets. A: Insulin secretion was measured in a dynamic perifusion system (n = 5)
where control islets (black diamonds) or composite MSC–islets (light triangles) were initially challenged with low-glucose (1.67 mmol/L)
followed by high-glucose stimulation (20 mmol/L, 42–78 min). B: The ratio of insulin versus total DNA (pmol  L
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1) in islet
homogenates (n = 3). C: Insulin-containing cells survived in vivo, indicated by insulin-staining of grafts of human islets and MSC–islets
transplanted under the kidney capsule of nude mice retrieved after 2 weeks (n = 3).
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Figure 3. Syngeneic transplantation of mouse MSC–islets. A: Control mouse islets (*) and mouse MSC–islets (**) were transplanted under
the kidney capsule of mice and retrieved after 28 days in vivo, showing enlargement of the MSC–islet graft (**) in comparison to control islet
graft (*) (n = 3). B: Close up of the MSC–islet graft. C: Section of mouse MSC–islet grafts after decalciﬁcation showing bone formation of
differentiated MSCs. Bar = 100 mm.
Composite mesenchymal stem cell islets 13in vitro the potential cellular rejection response
that can be triggered by transplanted islets in
MLIR. MSCs signiﬁcantly reduced proliferation
of lymphocytes, with possible importance in
co-transplantation of islets with MSCs, by induc-
ing a local immunosuppressive milieu surround-
ing the islets. We dissociated the islets to
optimize the contact between lymphocytes and
islet cells, since whole islets were unable to stimu-
late measurable levels of proliferation (data not
shown). During the dissociation of islets, naturally
other islet cells than beta cells, such as alpha, delta,
and pancreatic polypeptide (PP) cells, but also
endothelial cells, are released, and they most likely
contribute to stimulate proliferation. Beta cells
express low levels of human leukocyte antigen
(HLA) class I and do not express HLA II (40).
Only a small fraction of the non-endocrine
cells express HLA class DR, mainly macrophages
and endothelial cells (41), which may explain the
lower proliferation by responder lymphocytes.
Other factors that can alter the immunogenicity of
islets are the production of inﬂammatory cytokines
(42) and the presence of acinar cells in the disso-
ciated islets that can suppress the proliferative
response of lymphocytes (43). The effect of com-
posite MSC–islets on interactions with blood
did not show any increased activation, which
is beneﬁcial for intraportal transplantation of
composite grafts.
MSCs could play an important role in suppressing
cellular rejection of transplanted islets. Fiorina et al.
suggested that murine MSCs protect the pancreas
from autoimmune destruction in a NOD mouse
model by recruiting the MSCs to pancreatic lymph
nodes to suppress T cells through the co-stimulatory
molecule programmed death-ligand 1 (PD-L1) (44).
Itakura and colleagues reduced rejection of
transplantation of pancreatic islets by co-transplan-
tation of MSCs. Diabetic rats receiving an intraportal
co-infusion of MSCs, bone-marrow cells, and
islets rejected the islets initially. However, half of
them developed stable mixed chimerism and
donor-speciﬁc immune tolerance, as shown by
the engraftment of donor skin and second-
set islet transplants and acute rejection of a third-
party skin (45).
Undesired differentiation of cells should always be
considered in transplantation studies using stem cells.
We have chosen to use human MSCs and human
islets of Langerhans. Our attempts to use syngeneic
models with mouse MSCs in composite islets resulted
in bone formation under the kidney capsule. This
phenomenon was ﬁrst shown by Friedenstein et al. in
1966 (46). Human MSCs appear to be less inclined to
form bone in vivo unless the correct stimuli are
present (47). In this study we have not experienced
bone differentiation of human MSCs transplanted to
nu/nu mice.
In this study, we wanted to determine the outcome
of coating pancreatic islets with MSCs by investi-
gating islet function and the effect on innate and
adaptive immunity. To conclude, we show that
MSCs can both cover the surface and colonize the
inner core of pancreatic islets. The MSCs inhibited
lymphocyte proliferation induced by islet cells,
whereas the innate immune reactions were
unaltered. Formation of composite islet grafts also
facilitated delivery of MSCs together with the islets
when transplanted under the kidney capsule. From
these data we have shown that the MSCs can be
bound to the surface of the islets to ensure delivery
at the site of transplantation where they may
have promising effects oni m m u n er e g u l a t i o nt o
support engraftment of transplanted islets of
Langerhans.
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